Please login to the form below

Not currently logged in
Email:
Password:

S-A collaborates to develop antibodies

S-A has entered into a global collaboration agreement to develop an antibody against an antigen present on the surface of carcinoma cells

Sanofi-aventis (S-A) has entered into a global collaboration agreement with Micromet to develop an antibody against an antigen present on the surface of carcinoma cells.

Under the terms of the agreement, Micromet will take responsibility for discovery, research and development of the antibody through the phase I clinical trial process, under the supervision of a Joint Steering Committee. Further development and worldwide commercialisation of the antibody will be sanofi-aventis' responsibility.

Upon signing the agreement, S-A will make an upfront payment of €8m to Micromet. Additionally, Micromet will be eligible for up to €312m in milestone and royalty payments.

"Micromet's BiTE antibodies represent a promising new approach to treating cancer," declared Marc Cluzel, senior vice-resident R&D, sanofi-aventis. "We believe BiTE antibodies have the potential to significantly expand the treatment options that we can offer to cancer patients in the future."

29th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell - Cake

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics